These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 16796179)
21. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Vincent JL; Bernard GR; Beale R; Doig C; Putensen C; Dhainaut JF; Artigas A; Fumagalli R; Macias W; Wright T; Wong K; Sundin DP; Turlo MA; Janes J Crit Care Med; 2005 Oct; 33(10):2266-77. PubMed ID: 16215381 [TBL] [Abstract][Full Text] [Related]
22. International integrated database for the evaluation of severe sepsis and drotrecogin alfa (activated) therapy: analysis of efficacy and safety data in a large surgical cohort. Payen D; Sablotzki A; Barie PS; Ramsay G; Lowry S; Williams M; Sarwat S; Northrup J; Toland P; McL Booth FV Surgery; 2006 Nov; 140(5):726-39. PubMed ID: 17084715 [TBL] [Abstract][Full Text] [Related]
23. Prescribing indications based on successful clinical trials in sepsis: a difficult exercise. Carlet J Crit Care Med; 2006 Feb; 34(2):525-9. PubMed ID: 16424736 [No Abstract] [Full Text] [Related]
24. ADDRESS (ADministration of DRotrecogin alfa [activated] in Early stage Severe Sepsis) long-term follow-up: one-year safety and efficacy evaluation. Laterre PF; Abraham E; Janes JM; Trzaskoma BL; Correll NL; Booth FV Crit Care Med; 2007 Jun; 35(6):1457-63. PubMed ID: 17452935 [TBL] [Abstract][Full Text] [Related]
26. [Can we still afford progress in intensive care medicine? Re: the article from DMW 1-2/2004]. Rustige J Dtsch Med Wochenschr; 2004 Jul; 129(31-32):1698; author reply 1699-70. PubMed ID: 15273923 [No Abstract] [Full Text] [Related]
27. Drotrecogin alfa (activated) in severe sepsis. LaRosa SP N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16395833 [No Abstract] [Full Text] [Related]
28. Clinical review: Drotrecogin alfa (activated) as adjunctive therapy for severe sepsis--practical aspects at the bedside and patient identification. Laterre PF; Wittebole X Crit Care; 2003 Dec; 7(6):445-50. PubMed ID: 14624684 [TBL] [Abstract][Full Text] [Related]
29. [Xigris--activated protein C]. Tønnesen EK Ugeskr Laeger; 2004 Mar; 166(11):1002-4. PubMed ID: 15049235 [No Abstract] [Full Text] [Related]
30. Drotrecogin alfa (activated) in severe sepsis. Friedrich JO N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16394311 [No Abstract] [Full Text] [Related]
31. Meeting unmet needs in patients with sepsis: the role of drotrecogin alfa (activated). Morris PE Am J Crit Care; 2003 Mar; 12(2):94-7. PubMed ID: 12625165 [No Abstract] [Full Text] [Related]
32. Drotrecogin alfa (activated) in severe sepsis. Baillie JK; Murray G N Engl J Med; 2006 Jan; 354(1):94-6; author reply 94-6. PubMed ID: 16395834 [No Abstract] [Full Text] [Related]
33. Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial. Eichacker PQ; Danner RL; Suffredini AF; Cui X; Natanson C Crit Care Med; 2005 Oct; 33(10):2426-8. PubMed ID: 16215410 [No Abstract] [Full Text] [Related]
34. Results of severe sepsis treatment program using recombinant human activated protein C in Poland. Kübler A; Mayzner-Zawadzka E; Durek G; Gaszyński W; Karpel E; Mikaszewska-Sokolewicz M; Majak P Med Sci Monit; 2006 Mar; 12(3):CR107-12. PubMed ID: 16501420 [TBL] [Abstract][Full Text] [Related]
35. Severe sepsis and therapy with activated protein C. Parrillo JE N Engl J Med; 2005 Sep; 353(13):1398-400. PubMed ID: 16192486 [No Abstract] [Full Text] [Related]
36. Drotrecogin alfa: new preparation. For some cases of severe sepsis? Prescrire Int; 2003 Apr; 12(64):55-7. PubMed ID: 12674116 [TBL] [Abstract][Full Text] [Related]
37. What is the role of recombinant activated protein C in the management of sepsis? Alvarado J; Castro R Medwave; 2016 Dec; 16(Suppl5):e6801. PubMed ID: 28032853 [TBL] [Abstract][Full Text] [Related]
38. ENHANCE: results of a global open-label trial of drotrecogin alfa (activated) in children with severe sepsis. Goldstein B; Nadel S; Peters M; Barton R; Machado F; Levy H; Haney DJ; Utterback B; Williams MD; Giroir BP Pediatr Crit Care Med; 2006 May; 7(3):200-11. PubMed ID: 16575354 [TBL] [Abstract][Full Text] [Related]
39. Analysis of efficacy and safety of drotrecogin alfa (activated) in surgical patients, using an international integrated database. Payen D; Sundin DP; Nelson DR; Williams MD Surgery; 2007 Sep; 142(3):426-7. PubMed ID: 17723900 [No Abstract] [Full Text] [Related]
40. Role of activated protein C in the pathophysiology of severe sepsis. Dettenmeier P; Swindell B; Stroud M; Arkins N; Howard A Am J Crit Care; 2003 Nov; 12(6):518-24; quiz 525-6. PubMed ID: 14619357 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]